Their results not only linked the phenotype of CD4+ TILs to clonotypes, but also unveiled that tumor-specific CD4+ Treg clonotypes could be directly stimulated by HLA class II positive melanoma in the presence of extremely high tumor mutation burden (TMB). This evidence concerns the gene CD4 and neoplasm.